A panel of 45 miRNAs was measured in exosomes derived from a cohort of 435 breast cancer patients enrolled in the GeparSixto trial (NCT01426880, 211 HER2+ and 224 TNBC), revealing significant differences in the expression pattern according to their different tumor biology. Here, ERBB2 is linked to breast carcinoma.